SEPT3 Antibody

What is SEPT3 and why is it significant in neurobiological research?

SEPT3 (Septin 3) is a filament-forming cytoskeletal GTPase primarily expressed in neuronal tissues. It belongs to the septin family of proteins that play essential roles in cytoskeletal organization, membrane dynamics, and cytokinesis . SEPT3 is particularly significant in neurobiological research because:

• It is predominantly expressed in the central nervous system as a neuronal-specific septin

• It functions as a developmentally regulated phosphoprotein involved in neuronal autophagy

• It contributes to cytoskeletal architecture through GTP-dependent polymerization

• It participates in various neuronal processes through phosphorylation-dependent mechanisms

When designing neurobiological experiments, researchers should consider SEPT3's tissue-specific expression pattern when selecting appropriate control tissues and cell lines.

SEPT3 belongs to the SEPT3 subgroup of the septin family (which includes SEPT9 and SEPT12) and shares the following structural and functional relationships with other septins:

• Core domain structure: Contains a conserved GTP-binding domain characteristic of the septin family

• Complex formation: SEPT3 can form heteromeric complexes with other septins, particularly SEPT5, SEPT6, SEPT7, and SEPT11

• Functional redundancy: Some functions may overlap with other neuronal septins, requiring careful knockout validation studies

• Tissue specificity: While other septins are widely expressed, SEPT3 shows neuronal specificity, suggesting unique neuronal functions

When designing experiments targeting SEPT3, researchers should carefully consider antibody specificity to avoid cross-reactivity with other septin family members, particularly those sharing high sequence homology.

What are the optimal conditions for using SEPT3 antibodies in Western blotting?

For optimal Western blotting results with SEPT3 antibodies, the following protocol parameters have been validated in the literature:

The predicted molecular weight of 41 kDa should be confirmed, with potential variation based on post-translational modifications, particularly phosphorylation status .

How can researchers effectively use SEPT3 antibodies for immunohistochemistry?

For successful immunohistochemical detection of SEPT3, researchers should implement the following validated approach:

• Tissue preparation:

  • Paraffin-embedded sections (4-6 μm thick)

  • Antigen retrieval using citrate buffer (pH 6.0) or alternatively TE buffer (pH 9.0)

• Staining protocol:

  • Primary antibody dilution: 1:50-1:500 (optimize for each antibody)

  • Recommended incubation: Overnight at 4°C

  • Secondary antibody: Compatible with host species (typically 60 minutes at room temperature)

  • Visualization: Diaminobenzidine (DAB) staining

• Controls and validation:

  • Positive control tissues: Brain tissue (particularly cerebellum and hippocampus)

  • Negative controls: Tissues known to lack SEPT3 expression

  • Blocking peptide controls to confirm specificity

• Interpretation:

  • SEPT3 is predominantly cytoplasmic in neuronal cells

  • In cancer tissues like TNBC, increased cytoplasmic staining correlates with disease progression

What methodological approaches are recommended for studying SEPT3 phosphorylation?

SEPT3 phosphorylation, particularly at Ser-91 by cGMP-dependent protein kinase (PKG), can be studied using these validated approaches:

• Phospho-specific antibodies:

  • Use antibodies specifically targeting phosphorylated Ser-91

  • Appropriate controls: unphosphorylated protein, phosphatase-treated samples

• Site-directed mutagenesis:

  • Generate S91A or S92A mutants to confirm phosphorylation sites

  • Express as GFP-tagged fusion proteins for visualization and immunoprecipitation

• In vitro phosphorylation assays:

  • Recombinant PKG with purified SEPT3 protein

  • 32P-ATP labeling to track phosphorylation

• Cellular translocation studies:

  • Monitor SEPT3 translocation from membrane to cytosol following phosphorylation

  • Use subcellular fractionation with Western blotting

• Functional validation:

  • Synaptosomal preparations treated with cGMP pathway activators like 8-pCPT-cGMP

  • Correlate phosphorylation with functional outcomes in neurons

How can SEPT3 antibodies be utilized in studies of neuronal autophagy regulation?

SEPT3 has been implicated in neuronal autophagy regulation, and researchers can leverage SEPT3 antibodies for these mechanistic studies:

• Autophagy induction monitoring:

  • Track SEPT3 level changes during autophagy using quantitative immunoblotting

  • Co-localization studies with autophagy markers (LC3, p62) using immunofluorescence

• Septin oligomerization analysis:

  • Use co-immunoprecipitation with SEPT3 antibodies to identify autophagy-dependent septin complex formation

  • Analyze high-molecular-weight complexes via blue native PAGE

• Correlation with autophagic flux:

  • Combine SEPT3 immunostaining with autophagosome and autolysosome markers

  • Employ autophagy modulators (rapamycin, bafilomycin A1) and monitor SEPT3 expression/localization changes

• Functional studies:

  • SEPT3 knockdown/overexpression combined with autophagy assays

  • Rescue experiments with wild-type versus phospho-mutant SEPT3

These approaches can help elucidate the precise molecular mechanisms through which SEPT3 contributes to neuronal autophagy regulation.

What strategies can be employed to investigate SEPT3 in hetero-oligomeric septin complexes?

Investigating SEPT3's participation in septin complexes requires specialized approaches:

• Co-immunoprecipitation (Co-IP):

  • Use SEPT3 antibodies to pull down native complexes

  • Identify interacting septins (SEPT5, SEPT6, SEPT7, SEPT11) using specific antibodies

  • Validate using reciprocal Co-IP with antibodies against partner septins

• Recombinant co-expression systems:

  • Co-express SEPT3 with other septins in HEK293 cells

  • Sequential removal of individual septins to determine complex dependency

  • Test complex formation using RC-IIFA (recombinant cell-based indirect immunofluorescence assays)

• Structural analysis:

  • Electron microscopy of purified septin complexes

  • Mass spectrometry of intact complexes to determine stoichiometry

• Fluorescence techniques:

  • FRET analysis between fluorescently-tagged septins

  • Fluorescence correlation spectroscopy to detect complex formation

• Functional validation:

  • Analyze effects of mutations at septin-septin interfaces

  • Correlate complex integrity with cellular functions

How can researchers employ epitope mapping to characterize novel SEPT3 antibodies?

Epitope mapping is crucial for understanding antibody specificity, particularly for multispecific antibodies. Researchers can implement these methodological approaches:

• Peptide array analysis:

  • Create overlapping peptide fragments spanning the SEPT3 sequence

  • Test antibody binding to identify minimal epitope regions

  • Compare mapped epitopes with other septin family members to assess cross-reactivity potential

• Mutagenesis approaches:

  • Generate point mutations in predicted epitope regions

  • Assess binding affinity changes using surface plasmon resonance (SPR)

  • Create humanized or chimeric constructs to localize epitope regions

• Competitive binding assays:

  • Use competing peptides to block antibody binding

  • Employ ELISA to quantify competitive displacement

  • Assess if multiple epitopes share binding regions on the antibody

• Structural biology approaches:

  • X-ray crystallography of antibody-peptide complexes

  • Hydrogen-deuterium exchange mass spectrometry to map interaction interfaces

• Validation in biological samples:

  • Test specificity using tissues from SEPT3 knockout models

  • Pre-absorption with recombinant proteins to confirm specificity

What are common pitfalls in SEPT3 detection and how can they be addressed?

Researchers frequently encounter several challenges when working with SEPT3 antibodies:

Methodical validation using appropriate controls is essential for addressing these challenges and ensuring experimental reliability.

How should researchers design validation studies for new SEPT3 antibodies?

A comprehensive validation strategy for new SEPT3 antibodies should include:

• Specificity testing:

  • Western blot analysis using recombinant SEPT3 protein

  • Comparative analysis with other septin family members

  • Testing in SEPT3-knockout or knockdown systems

  • Pre-absorption with immunizing peptide/protein

• Application-specific validation:

  • For Western blotting: Verify correct molecular weight (41 kDa)

  • For IHC: Confirm tissue distribution pattern matches known expression

  • For IP: Demonstrate ability to enrich SEPT3 from complex mixtures

  • For FC: Validate using cells with known SEPT3 expression levels

• Epitope characterization:

  • Map the specific epitope using peptide arrays or truncation mutants

  • Assess epitope conservation across species for cross-reactivity potential

  • Determine if epitope includes post-translational modification sites

• Quantitative performance metrics:

  • Determine detection limits, linear range, and reproducibility

  • Calculate affinity constants using SPR or similar techniques

  • Assess lot-to-lot consistency if producing multiple batches

Documentation of these validation steps enhances experimental reproducibility and reliability.

How can SEPT3 antibodies be employed in cancer biomarker research?

SEPT3 has emerging potential as a cancer biomarker, particularly in triple-negative breast cancer (TNBC). Researchers can implement these methodological approaches:

• Tissue microarray (TMA) analysis:

  • Standardized IHC protocols with SEPT3 antibodies (1:500 dilution)

  • Quantitative scoring systems for expression levels

  • Correlation with clinical parameters (TNM stage, lymph node metastasis, Ki67 levels, histological grade)

• Prognostic value assessment:

  • Kaplan-Meier survival analysis stratified by SEPT3 expression

  • Multivariate Cox regression to determine independent prognostic value

  • Integration with other established biomarkers

• Mechanistic studies:

  • Investigation of SEPT3's role in cancer cell migration and invasion

  • Correlation with epithelial-mesenchymal transition markers

  • Functional validation through knockdown/overexpression experiments

• Biospecimen analysis standardization:

  • Sample preparation protocols optimized for SEPT3 detection

  • Internal controls for normalization

  • Blinded assessment to minimize bias

Recent findings demonstrate that SEPT3 expression is significantly elevated in TNBC tissues compared to normal tissues and is associated with unfavorable prognosis, TNM stage, lymph node metastasis, and histological grade .

What methodological considerations are important when using SEPT3 antibodies in autoimmune disorder research?

The recent identification of SEPT3 as an autoantigen in paraneoplastic cerebellar ataxia requires specific methodological approaches:

• Detection of anti-SEPT3 autoantibodies:

  • Recombinant cell-based indirect immunofluorescence assays (RC-IIFA) using cells expressing septin complexes

  • Tissue-based immunofluorescence on rat/primate cerebellum sections

  • Confirmation using individual septin expression versus complexes

• Specificity validation:

  • Pre-absorption studies with recombinant SEPT3 or septin complexes

  • Testing with cells expressing septin combinations missing individual septins

  • Cross-validation with mass spectrometry after immunoprecipitation

• Clinical correlation studies:

  • Screening of cerebrospinal fluid and serum samples

  • Correlation with neurological symptoms and cancer types

  • Response to immunotherapy assessment

• Tumor analysis:

  • IHC for SEPT3 expression in associated tumors (melanoma, small cell lung cancer)

  • Correlation between tumor SEPT3 expression and autoantibody titers

These approaches have identified SEPT3 as a novel autoantibody target in patients with paraneoplastic cerebellar syndromes, with antibody detection possible using RC-IIFA with HEK293 cells expressing the septin-3/5/6/7/11 complex .

How should researchers approach the integration of SEPT3 antibody-based techniques with other methodologies in multi-omics studies?

For comprehensive characterization of SEPT3 biology, integration with other -omics approaches is valuable:

• Integration with transcriptomics:

  • Correlation of protein expression (detected by antibodies) with mRNA levels

  • Analysis of SEPT3 splice variants and their functional implications

  • Single-cell approaches to identify cell-type specific expression patterns

• Proteomics integration:

  • Immunoprecipitation with SEPT3 antibodies followed by mass spectrometry

  • Identification of post-translational modifications and interacting partners

  • Correlation with total proteome data from tissues/cells of interest

• Functional genomics coordination:

  • CRISPR-based SEPT3 manipulation combined with antibody-based readouts

  • Phosphoproteomics to identify signaling networks affected by SEPT3

  • Correlation with phenotypic assays for functional validation

• Data integration challenges:

  • Standardization of antibody-based quantification for cross-platform comparison

  • Statistical approaches for multi-omics data integration

  • Visualization tools for complex datasets

This multi-modal approach provides a more comprehensive understanding of SEPT3's roles in normal physiology and disease contexts than any single methodology alone.